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The optimal approach for empirical antibiotic therapy in patients with severe sepsis and septic shock
remains controversial. A retrospective cohort study was conducted in the intensive care units of a university
hospital. The data from 760 patients with severe sepsis or septic shock associated with Gram-negative
bacteremia was analyzed. Among this cohort, 238 (31.3%) patients received inappropriate initial antimicrobial
therapy (IIAT). The hospital mortality rate was statistically greater among patients receiving IIAT compared
to those initially treated with an appropriate antibiotic regimen (51.7% versus 36.4%; P < 0.001). Patients
treated with an empirical combination antibiotic regimen directed against Gram-negative bacteria (i.e.,
-lactam plus aminoglycoside or fluoroquinolone) were less likely to receive IIAT compared to monotherapy
(22.2% versus 36.0%; P < 0.001). The addition of an aminoglycoside to a carbapenem would have increased
appropriate initial therapy from 89.7 to 94.2%. Similarly, the addition of an aminoglycoside would have
increased the appropriate initial therapy for cefepime (83.4 to 89.9%) and piperacillin-tazobactam (79.6 to
91.4%). Logistic regression analysis identified IIAT (adjusted odds ratio [AOR], 2.30; 95% confidence interval
[CI]  1.89 to 2.80) and increasing Apache II scores (1-point increments) (AOR, 1.11; 95% CI  1.09 to 1.13)
as independent predictors for hospital mortality. In conclusion, combination empirical antimicrobial therapy
directed against Gram-negative bacteria was associated with greater initial appropriate therapy compared to
monotherapy in patients with severe sepsis and septic shock. Our experience suggests that aminoglycosides
offer broader coverage than fluoroquinolones as combination agents for patients with this serious infection.
Bacterial resistance to antibiotics creates a therapeutic chal-
lenge for clinicians when treating patients with a known or
suspected infection. Increasing rates of resistance lead many
clinicians to empirically treat patients with multiple broad-
spectrum antibiotics, which can perpetuate the cycle of increas-
ing resistance and create an economic burden to society (4, 7).
Conversely, inappropriate initial antimicrobial therapy (IIAT),
defined as an antimicrobial regimen that lacks in vitro activity
against the isolated organism(s) responsible for the infection,
can lead to treatment failures and adverse patient outcomes
(21). IIAT is a potentially modifiable factor that has also been
linked to increased mortality in patients with serious infections
(11, 16, 20, 25). Individuals with severe sepsis and septic shock
appear to be at particularly high risk of excess mortality when
IIAT is administered (10, 13, 14, 24). The most recent Surviv-
ing Sepsis Guidelines recommend empirical combination ther-
apy targeting Gram-negative bacteria, particularly for patients
with known or suspected Pseudomonas infections, as a means
to decrease the likelihood of administering IIAT (9). However,
the authors of this guideline acknowledge that “no study or
meta-analysis has convincingly demonstrated that combination
therapy produces a superior clinical outcome for individual
pathogens in a particular patient group.”
The de-escalation approach to antimicrobial therapy for se-
rious infections is a treatment strategy that attempts to provide
appropriate initial antimicrobial therapy to reduce the risk of
negative patient outcomes while also avoiding the conse-
quences of excessive or unnecessary antibiotic administration
(22). Appropriate initial antimicrobial selection is usually
based on an individual patient’s risk profile for infection with
potentially antibiotic-resistant bacteria, fungi, or molds and
other opportunistic microorganisms. Avoiding unnecessary use
of antibiotics occurs by narrowing the spectrum or number of
antimicrobial agents once the etiologic cause of the infection
and the patient’s response to the initial treatment are evalu-
ated, while also using the shortest course of antibiotic therapy
that is clinically indicated. The initial use of combination ther-
apy for Gram-negative bacteria is usually recommended in
de-escalation strategies for serious infections (2). Then again,
there is limited published data supporting such a strategy,
especially for patients with severe sepsis or septic shock.
Therefore, we performed a study with the main goal of deter-
mining whether combination antimicrobial therapy directed
against Gram-negative bacteria was associated with lower hos-
pital mortality in patients with severe sepsis and septic shock.
MATERIALS AND METHODS
Study location and patients. This study was conducted at a university-affili-
ated, urban teaching hospital: Barnes-Jewish Hospital (1200 beds). During a
* Corresponding author. Mailing address: Division of Pulmonary
and Critical Care Medicine, Washington University School of Medi-
cine, 660 South Euclid Avenue, Campus Box 8052, St. Louis, MO
63110. Phone: (314) 454-8764. Fax: (314) 454-5571. E-mail: mkollef
@dom.wustl.edu.
 Published ahead of print on 16 February 2010.
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6-year period (January 2002 to December 2007), all hospitalized patients with a
positive blood culture for Gram-negative bacteria were eligible for this investi-
gation. This study was approved by the Washington University School of Med-
icine Human Studies Committee.
Study design and data collection. A retrospective cohort study design was
used. Two investigators (J.A.D. and R.M.R.) identified potential study patients
by the presence of a positive blood culture for Gram-negative bacteria combined
with primary or secondary ICD-9-CM codes indicative of acute organ dysfunc-
tion. Based on the initial study database construction, three investigators
(E.C.W., J.K., and M.P.) merged patient-specific data from the automated hos-
pital medical records, microbiology database, and pharmacy database of Barnes-
Jewish Hospital to complete the clinical database under the auspices of the
definitions described below.
The baseline characteristics collected by the study investigators included: age,
gender, race, the presence of congestive heart failure, chronic obstructive pul-
monary disease, diabetes mellitus, chronic liver disease, underlying malignancy,
and end-stage renal disease requiring renal replacement therapy. All cause
hospital mortality was evaluated as the primary outcome variable. Secondary
outcomes evaluated included the occurrence of renal toxicity and acquisition of
Clostridium difficile-associated diarrhea (CDAD). Acute Physiology and Chronic
Health Evaluation II (APACHE II) (19) and Charlson comorbidity scores were
calculated to evaluate severity of illness based on clinical data present during the
24 h after the positive blood cultures were drawn. This was done since we
included patients with community-acquired infections who only had clinical data
available after blood cultures were drawn.
Definitions. All definitions were selected prospectively as part of the original
study design. Cases of Gram-negative bacteremia were classified into mutually
exclusive groups comprised of either community-acquired or health care-associ-
ated infection. Patients with health care-associated bacteremia were categorized
as community-onset or hospital-onset as previously described (18). In brief,
patients with health care-associated community-onset bacteremia had the posi-
tive culture obtained within the first 48 h of hospital admission in combination
with one or more of the following risk factors: (i) residence in a nursing home,
rehabilitation hospital, or other long-term nursing facility; (ii) previous hospital-
ization within the immediately preceding 12 months; (iii) receiving outpatient
hemodialysis, peritoneal dialysis, wound care, or infusion therapy necessitating
regular visits to a hospital-based clinic; and (iv) having an immunocompromised
state. Patients were classified as having health care-associated hospital-onset
bacteremia when the culture was obtained 48 h or more after admission. Com-
munity-acquired bacteremia occurred in patients without healthcare risk factors
and a positive blood culture within the first 48 h of admission. Prior antibiotic
exposure was defined as having occurred within the previous 30 days from the
onset of severe sepsis or septic shock. Renal toxicity was defined as a 0.5-mg/dl
increase in the serum creatinine in conjunction with a 50% increase in the serum
creatinine from the day therapy was initiated for Gram-negative bacteremia. In
addition, the need for renal replacement therapy stemming from the episode of
renal toxicity was collected. CDAD was defined by the presence of diarrhea or
pseudomembranous colitis and a positive assay for Clostridium difficile toxin A,
toxin B, or both toxins A and B occurring after the index case of Gram-negative
bacteremia.
To be included in the analysis, patients had to meet criteria for severe sepsis
based on discharge ICD-9-CM codes for acute organ dysfunction as previously
described (3). The organs of interest included the heart, lungs, kidneys, bone
marrow (hematologic), brain, and liver. Patients were classified as having septic
shock if vasopressors (norepinephrine, dopamine, epinephrine, phenylephrine,
or vasopressin) were initiated within 24 h of the blood culture collection date and
time. Antimicrobial treatment was classified as being appropriate if the initially
prescribed antibiotic regimen was active against the identified pathogen based on
in vitro susceptibility testing and administered within 24 h of blood culture
collection. For patients with polymicrobial infection the initial antimicrobial
regimen had to be active against all identified pathogens in order to be classified
as appropriate. Appropriate antimicrobial treatment also had to be prescribed
for at least 24 h. However, the total duration of antimicrobial therapy was at the
discretion of the treating physicians.
Antimicrobial monitoring. From January 2002 through the present Barnes-
Jewish Hospital utilized an antibiotic control program to help guide antimicro-
bial therapy. During this time the use of cefepime and gentamicin was unre-
stricted. However, the initiation of intravenous ciprofloxacin, imipenem/
cilastatin, meropenem, or piperacillin-tazobactam was restricted and required
preauthorization from either a clinical pharmacist or infectious diseases physi-
cian. Each intensive care unit had a clinical pharmacist who reviewed all antibi-
otic orders to ensure that dosing and interval of antibiotic administration was
adequate for individual patients based on body size, renal function, and the
resuscitation status of the patient. After daytime hours the on-call clinical phar-
macist reviewed and approved the antibiotic orders. Starting in June 2005, a
sepsis order set was implemented in the Emergency Department, general med-
ical wards, and the intensive care units with the intent of standardizing empirical
antibiotic selection for patients with sepsis based on the infection type (i.e.,
community-acquired pneumonia, health care-associated pneumonia, intra-ab-
dominal infection, etc.) and the local antibiogram (26, 30). However, antimicro-
bial selection, dosing, and de-escalation of therapy were still optimized by clinical
pharmacists in these clinical areas.
Antimicrobial susceptibility testing. The microbiology laboratory performed
antimicrobial susceptibility of the Gram-negative bacterial isolates by the Kirby-
Bauer disk diffusion method according to guidelines and breakpoints established
by the Clinical Laboratory and Standards Institute (CLSI), using 150-mm round
plates of Mueller-Hinton agar (BBL/Becton Dickinson, Cockeysville, MD). A
technologist experienced in reading zones of inhibition with a ruler against a
black background measured zone diameters manually.
Data analysis. Continuous variables were reported as mean  the standard
deviation. The Student t test was used when we compared normally distributed
data, and the Mann-Whitney U test was used to analyze non-normally distributed
data. Categorical data was expressed as frequency distributions, and the chi-
square test was used to determine whether differences existed between groups.
We performed multiple logistic regression analysis to identify clinical risk factors
that were associated with hospital mortality (SPSS, Inc., Chicago, IL). All risk
factors that were significant at 0.2 in the univariate analysis were included in the
multivariable analyses. All tests were two-tailed, and a P value of 0.05 was
determined to represent statistical significance.
RESULTS
Patient characteristics. A total of 760 patients were included
in the study, of whom 522 (68.7%) received initially appropri-
ate antimicrobial treatment, and 238 (31.3%) received IIAT
for severe sepsis or septic shock associated with Gram-negative
bacteremia. The mean age was 59.3  16.3 (range, 18 to 99),
with 399 (52.5%) males and 361 (47.5%) females. The infec-
tion sources included community-acquired (n  72, 9.5%),
healthcare-associated community-onset (n  269, 35.4%) and
healthcare-associated hospital-onset (n  419, 55.1%). Pa-
tients receiving IIAT were statistically less likely to have either
community-acquired or healthcare-associated community-on-
set sources of infection and were more likely to have health-
care-associated hospital-onset sources of infection compared
to patients receiving appropriate initial treatment (Table 1).
Patients treated with IIAT were also statistically more likely to
have chronic kidney disease, diabetes mellitus, respiratory or-
gan dysfunction, the lungs as the source of infection, mechan-
ical ventilation, and prior antibiotic exposure and were less
likely to have active malignancy and the urinary tract as the
source of their infection (Table 1).
Microbiology. Among the 825 Gram-negative bacteria iso-
lated from blood, the most common included Escherichia coli
(28.1%), Klebsiella species (22.8%), Pseudomonas aeruginosa
(16.0%), Enterobacter species (9.2%), and Acinetobacter spe-
cies (7.6%) (Table 2). Patients receiving IIAT were statistically
more likely to be infected with extended-spectrum -lactamase
(ESBL)-producing Klebsiella pneumonia, Achromobacter spe-
cies, Acinetobacter species, and Stenotrophomonas maltophilia
and less likely to be infected with Escherichia coli, non-ESBL-
producing Klebsiella pneumoniae and to have polymicrobial
bacteremia compared to patients receiving initial appropriate
therapy. The pathogen-specific hospital mortality rate was sta-
tistically greater for patients with bacteremia attributed to
Acinetobacter species, Pseudomonas aeruginosa, and Stenotro-
phomonas maltophilia who received IIAT (Table 2).
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Antimicrobial susceptibility. The antimicrobial susceptibil-
ities of the Gram-negative bacterial isolates are shown in
Table 3 with overall susceptibility being greatest for imipenem/
meropenem, followed by, in descending order, gentamicin,
cefepime, piperacillin-tazobactam, and ciprofloxacin. For indi-
vidual bacterial species Acinetobacter species and Stenotropho-
monas maltophilia had the lowest overall susceptibility to all
antimicrobial agents tested. Overall, 247 (30.0%) of the iso-
lates were treated with IIAT. IIAT was most common for S.
maltophilia, followed by Achromobacter species, Acinetobacter
species, and Salmonella species. Among the 359 (43.5%) bac-
terial isolates resistant to cefepime, imipenem/meropenem, or
piperacillin-tazobactam, 99 (27.6%) were susceptible to cipro-
floxacin, and 173 (48.2) were susceptible to gentamicin (Table
4). The incremental increases in the appropriateness of initial
antimicrobial therapy for patients treated with cefepime, imi-
penem or meropenem, and piperacillin-tazobactam if cipro-
floxacin or gentamicin were added to their antibiotic regimens
are shown in Table 5. IIAT was statistically greatest for pa-
tients receiving monotherapy compared to combination anti-
microbial therapy directed against Gram-negative bacteria
(36.0% versus 22.2%; P  0.001) (Fig. 1). Among the 238
patients initially receiving IIAT, 174 (73.1%) were switched to
definitive therapy within 48 h of having their cultures drawn.
Among the 257 patients receiving initial combination therapy,
198 (77.0%) were switched to a single agent for definitive
therapy.
Specific individual pathogens. (i) Pseudomonas aeruginosa.
Among the 132 isolates, 41 (31.1%) received IIAT. Seventeen
of these isolates were initially treated with ciprofloxacin (n 
8), gentamicin (n  5), or another antibiotic (n  4) as the
combination agent. For the 36 isolates not treated with genta-
micin, 28 (77.8%) were susceptible to gentamicin and would
have received appropriate therapy if gentamicin were part of
the empirical regimen.
(ii) Acinetobacter species. Among the 63 isolates, 44 (69.8%)
received IIAT. Sixteen of these isolates were initially treated
with a combination regimen that included ciprofloxacin (n 
4), gentamicin (n  4), or another antibiotic (n  8) as the
combination agent. For the 40 isolates not treated with genta-
micin, 9 (22.5%) were susceptible to gentamicin and would
have received appropriate therapy if gentamicin were part of
the empirical regimen.
(iii) Escherichia coli. Among the 232 isolates, 41 (17.7%)
received IIAT. Nine of these isolates were initially treated with
a combination regimen that included ciprofloxacin (n  3),
gentamicin (n  4), or another antibiotic (n  2) as the com-
bination agent. For the 37 isolates not treated with gentamicin,
29 (78.4%) were susceptible to gentamicin and would have
received appropriate therapy if gentamicin were part of the
empirical regimen.
Outcomes and multivariate analysis. A total of 313 (41.2%)
patients died during hospitalization. Hospital mortality was
statistically greater for patients receiving IIAT compared to
those treated with appropriate initial therapy (51.7% versus
36.4%; P  0.001). Among the 238 patients receiving IIAT,
those switched to definitive therapy within 48 h of having their
cultures drawn had a statistically lower risk of hospital mortal-
ity compared to those whose therapy was not switched (44.8%
versus 70.3%; P  0.001). Hospital mortality and IIAT were
statistically greatest for patients with healthcare-associated
hospital-onset infections (Fig. 2). Patients with health care-
associated community-onset bacteremia had statistically
greater APACHE II scores compared to patients with health-
care-associated hospital-onset bacteremia (24.7  6.5 versus
23.4  6.6; P  0.012). Patients with healthcare-associated
community-onset bacteremia had statistically lower rates of
infection with Acinetobacter species (5.9% versus 10.5%; P 
0.039), Achromobacter species (0.4% versus 2.6%; P  0.034),
Serratia marcescens (1.9% versus 6.0%; P  0.010) and statis-
TABLE 1. Baseline characteristics
Variablea
Appropriate
antibiotic
therapy
Inappropriate
antibiotic
therapy
P
No. of subjects 522 238
Mean age (yr)  SD 59.9  16.5 57.7  15.8 0.082
No. of males (%) 283 (54.2) 116 (48.7) 0.161
Infection onset source
Community acquired 58 (11.1) 14 (5.9) 0.023
Healthcare-associated
community onset
210 (40.2) 59 (24.8) 0.001
Healthcare-associated
hospital onset
254 (48.7) 165 (69.3) 0.001
Underlying comorbidities
CHF 94 (18.0) 51 (21.4) 0.275
COPD 89 (17.0) 48 (20.2) 0.310
Chronic kidney disease 60 (11.5) 49 (20.6) 0.001
Hemodialysis 48 (9.2) 30 (12.6) 0.158
Liver disease 57 (10.9) 38 (16.0) 0.058
Active malignancy 179 (34.3) 64 (26.9) 0.042
Neutropeniab 44 (8.4) 14 (5.9) 0.220
Diabetes 104 (19.9) 65 (27.3) 0.024
Mean Charlson comorbidity
score  SD
4.8  3.7 4.8  3.6 0.994
Mean APACHE II score  SD 23.9 6.7 23.2  6.6 0.203
ICU admission 403 (77.2) 197 (82.8) 0.081
Vasopressors 303 (58.0) 141 (59.2) 0.756
Mechanical ventilation 269 (51.5) 149 (62.6) 0.004
Dysfunctional organ systems
Cardiovascular 323 (61.9) 147 (61.8) 0.976
Respiratory 304 (58.2) 164 (68.9) 0.005
Renal 285 (54.6) 123 (51.7) 0.454
Hepatic 40 (7.7) 15 (6.3) 0.502
Hematologic 152 (29.1) 79 (33.2) 0.257
Neurologic 33 (6.3) 14 (5.9) 0.872
2 dysfunctional organ
systems
352 (67.4) 175 (73.5) 0.091
Source of bloodstream
infection
Lungs 186 (35.6) 114 (47.9) 0.001
Urinary tract 169 (32.4) 60 (25.2) 0.046
Central venous catheter 45 (8.6) 12 (5.0) 0.102
Intra-abdominal 94 (18.0) 47 (19.7) 0.567
Unknown 38 (7.3) 13 (5.5) 0.435
Prior antibioticsc 172 (33.0) 144 (60.5) 0.001
a The values represent the “number of subjects (%)” except as noted. CHF,
congestive heart failure; COPD, chronic obstructive pulmonary disease;
APACHE, acute physiologic and chronic health evaluation; ICU, intensive care
unit.
b Fewer than 500 neutrophils per mm3 of blood.
c That is, in the preceding 30 days.
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tically higher rates of infection with non-ESBL-producing
Escherichia coli (37.2% versus 19.6%; P  0.001) and Proteus
mirabilis (8.2% versus 2.9%; P  0.002) compared to patients
with healthcare-associated hospital-onset bacteremia. Logistic
regression analysis identified IIAT (AOR, 2.30; 95% confi-
dence interval [CI]  1.89 to 2.80) and increasing APACHE II
scores (1-point increments) (adjusted odds ratio [AOR], 1.11;
95% CI  1.09 to 1.13) as independent predictors for hos-
pital mortality (Hosmer-Lemeshow goodness-of-fit test: 0.655).
The overall occurrence of renal toxicity was 14.5% (n 
110). The renal toxicity was similar for patients receiving com-
bination therapy and monotherapy (17.5% versus 12.7%; P 
0.075). There was a significant increase in renal toxicity for
patients receiving combination therapy with an aminoglycoside
TABLE 2. Microbiology
Bacteria
Appropriate antibiotic therapy
(n  522)
Inappropriate antibiotic therapy
(n  238)
Pa
No. of subjects
(%)
% Hospital
mortality
No. of subjects
(%)
% Hospital
mortality
Enterobacteriaceae
Citrobacter freundii 8 (1.5) 12.5 2 (0.8) 50.0 0.733 (0.378)
Other Citrobacter species 1 (0.2) 0.0 1 (0.4) 0.0 0.529 (—)
Enterobacter cloacae 40 (7.7) 32.5 16 (6.7) 37.5 0.765 (0.721)
Enterobacter aerogenes 10 (1.9) 10.0 4 (1.7) 50.0 1.0 (0.176)
Other Enterobacter species 3 (0.6) 0.0 3 (1.3) 66.7 0.384 (0.400)
Escherichia coli 188 (36.0) 31.9 37 (15.5) 29.7 0.001 (0.794)
ESBL Escherichia coli 3 (0.6) 66.7 4 (1.7) 25.0 0.214 (0.486)
Klebsiella oxytoca 10 (1.9) 30.0 3 (1.3) 66.7 0.764 (0.510)
Klebsiella pneumoniae 129 (24.7) 36.4 30 (12.6) 50.0 0.001 (0.170)
ESBL Klebsiella species 5 (1.0) 60.0 11 (4.6) 45.5 0.002 (1.0)
Morganella morganii 9 (1.7) 55.6 0 (0) 0.0 0.064 (—)
Proteus mirabilus 30 (5.7) 40.0 7 (2.9) 42.9 0.104 (1.0)
Providencia species 4 (0.8) 0.0 0 (0) 0.0 0.315 (—)
Salmonella species 2 (0.4) 0.0 4 (1.7) 0.0 0.081 (—)
Serratia marcescens 16 (3.1) 37.5 14 (5.9) 28.6 0.072 (0.709)
Nonfermenting Gram-negative rods
Achromobacter species 3 (0.6) 100.0 9 (3.8) 77.8 0.002 (1.0)
Acinetobacter species 19 (3.6) 26.3 44 (18.5) 61.4 0.001 (0.011)
Burkholderia species 1 (0.2) 0.0 1 (0.4) 0.0 0.529 (—)
Pseudomonas aeruginosa 91 (17.4) 47.3 41 (17.2) 68.3 1.0 (0.025)
Other Pseudomonas species 0 (0) 0.0 2 (0.8) 0.0 0.098 (—)
Stenotrophomonas maltophilia 4 (0.8) 0.0 16 (6.7) 87.5 0.001 (0.003)
Polymicrobial Gram negative 45 (8.6) 24.4 10 (4.2) 40.0 0.034 (0.434)
a P values in parentheses represent the comparison of hospital mortality for the two groups. “(—)” indicates analysis not performed.
TABLE 3. Antibiogram for Gram-negative bacterial isolatesa
Gram-negative bacterium Total no. ofisolates
No. of isolates (%) susceptible to:
Cefepime Ciprofloxacin Gentamicin Imipenem ormeropenem Piperacillin-tazobactam IIAT
Achromobacter spp. 12 3 (25) 6 (50) 0 (0) 12 (100) 9 (75) 9 (75)
Acinetobacter spp. 63 19 (30.2) 15 (23.8) 28 (44.4) 31 (49.2) 13 (20.6) 44 (69.8)
Burkholderia spp. 2 1 (50) 1 (50) 0 (0) 1 (50) 2 (100) 1 (50)
Citrobacter spp. 12 12 (100) 9 (75) 11 (91.7) 12 (100) 9 (75) 3 (25)
Enterobacter spp. 76 63 (82.9) 57 (75) 72 (94.7) 70 (92.1) 50 (65.8) 23 (30.3)
Escherichia coli 232 222 (95.7) 182 (78.4) 209 (90.1) 230 (99.1) 210 (90.5) 41 (17.7)
Klebsiella spp. 188 165 (87.8) 158 (84.0) 178 (94.7) 183 (97.3) 154 (81.9) 44 (23.4)
Morganella morganii 9 9 (100) 8 (88.9) 8 (88.9) 9 (100) 9 (100) 0 (0)
Proteus spp. 37 34 (91.9) 25 (67.6) 36 (97.3) 36 (97.3) 34 (91.9) 7 (18.9)
Providencia spp. 4 4 (100) 3 (75) 4 (100) 3 (75) 3 (75) 0 (0)
Pseudomonas aeruginosa 132 120 (90.9) 95 (72) 110 (83.3) 116 (87.9) 120 (90.9) 41 (31.1)
Salmonella spp. 6 5 (83.3) 6 (100) 6 (100) 6 (100) 6 (100) 4 (66.7)
Serratia marcescens 30 27 (90) 26 (86.7) 28 (93.3) 28 (93.3) 27 (90) 14 (46.7)
Stenotrophomonas maltophilia 20 6 (30) 11 (55) 8 (40) 0 (0) 7 (35) 16 (80)
Cumulative 823 690 (83.8) 602 (73.1) 698 (84.8) 737 (89.6) 653 (79.3) 247 (30)
a Excludes two isolates of other Pseudomonas species isolated from blood cultures. For Escherichia coli, there were 7 ESBL producers; for Klebsiella spp., there were
16 ESBL producers. EBSL, extended-spectrum -lactamase.
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compared to those not receiving an aminoglycoside (22.3%
versus 13.6%; P  0.014), although the need for renal replace-
ment therapy between these groups was not significantly dif-
ferent (2.5% versus 3.1%; P  1.0). The overall occurrence of
CDAD was 8.3%. CDAD developed in 8.2% of patients re-
ceiving combination therapy and 8.3% of patients receiving
monotherapy (P  0.933).
DISCUSSION
Our study demonstrated that IIAT is common among pa-
tients with Gram-negative bacteremia complicated by severe
sepsis or septic shock, especially for healthcare-associated hos-
pital-onset infections. Patients receiving IIAT had a statisti-
cally greater risk for hospital mortality presumably due, at least
in part, to the delay in initiating appropriate antimicrobial
treatment. We also showed that the addition of an antipseu-
domonal fluoroquinolone (ciprofloxacin) or an aminoglycoside
(gentamicin) to either imipenem or meropenem, piperacillin-
tazobactam, or cefepime increased overall susceptibility of
the antimicrobial regimens for the Gram-negative bacteria
associated with severe sepsis or septic shock. Furthermore,
combination therapy with an aminoglycoside resulted in
greater overall appropriateness of the antibiotic regimens
compared to combination therapy that included an anti-
pseudomonal fluoroquinolone.
Other investigators have attempted to evaluate the role of
combination antimicrobial treatment on the outcomes of pa-
tients with serious infections attributed to Gram-negative bac-
teria. The Canadian Trials Group compared a strategy of com-
bination antimicrobial therapy to a strategy of monotherapy
with broad-spectrum antibiotics for suspected late-onset ven-
tilator-associated pneumonia (15). Patients were allocated to
receive meropenem and ciprofloxacin or meropenem alone.
There was no difference in 28-day mortality between the com-
bination and monotherapy groups. The duration of intensive
care unit and hospital stay, clinical and microbiological treat-
ment response, emergence of antibiotic-resistant bacteria, iso-
lation of Clostridium difficile in stool, and fungal colonization
were also similar in the two groups. However, in a subgroup
of patients who had infection due to Pseudomonas species,
Acinetobacter species, and multidrug-resistant Gram-negative bac-
teria at enrollment, the appropriateness of initial antibiotics
(84.2% versus 18.8%, P  0.001) and microbiological eradica-
tion of infecting organisms (64.1% versus 29.4%, P  0.05)
were statistically higher in the combination group compared to
the monotherapy group.
Beardsley et al. also evaluated patients with hospital-ac-
quired pneumonia in the intensive care units of a teaching
hospital (6). These investigators found that the addition of an
FIG. 1. Percent of patients receiving inappropriate initial antimi-
crobial therapy (IIAT) according to combination antimicrobial treat-
ment. Other combination antimicrobial therapy included double -lac-
tam (non-carbapenem) combinations (n  33), -lactam carbapenem
combinations (n  16), and combinations including either tigecycline
or colistin (n  5).
FIG. 2. Hospital mortality and inappropriate initial antimicrobial
therapy (IIAT) according to classification of infection source. (P 
0.001 for differences in hospital mortality and IIAT).
TABLE 4. Activity of ciprofloxacin and gentamicin against cefepime-,
imipenem- or meropenem-, and piperacillin-tazobactam-resistant
Gram-negative bacteria associated with infectiona
Antibiotic with resistance No. of resistantisolates
No. of isolates (%)
susceptible to:
Ciprofloxacin Gentamicin
Cefepime 126 23 (18.3) 49 (38.9)
Imipenem or meropenem 78 20 (25.6) 34 (43.6)
Piperacillin-tazobactam 155 56 (36.1) 90 (58.1)
a Comparison of ciprofloxacin and gentamicin susceptibility for the resistant
isolates.
TABLE 5. Appropriateness of various antibiotic combinations
against Gram-negative pathogens in the study cohorta
Antibiotic
% Susceptible to at least one
antibiotic plus:
None Ciprofloxacin Gentamicin
Cefepime 83.4 86.4 89.9
Imipenem or meropenem 89.7 92.4 94.2
Piperacillin-tazobactam 79.6 87.0 91.4
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antipseudomonal fluoroquinolone did not increase the cumu-
lative susceptibility of cefepime, piperacillin-tazobactam, or
meropenem compared to using those agents alone (cumulative
susceptibility of 81 to 83% compared to 80 to 82% with the
addition of a fluoroquinolone). However, the addition of ami-
kacin to either cefepime, piperacillin-tazobactam, or mero-
penem increased the cumulative susceptibility of Gram-nega-
tive bacteria to 96%. A similar finding was made by Trouillet et
al., who showed that specific combinations of antimicrobials
were more likely to provide coverage of Gram-negative bacte-
ria causing ventilator-associated pneumonia compared to
other combinations (31). Specifically, a combination of a
carbapenem with an aminoglycoside was most likely to provide
appropriate treatment.
Paul et al. performed a meta-analysis of 64 clinical studies
with 7,586 patients comparing monotherapy to combination
antibiotic treatment for sepsis attributed to Gram-negative
bacteria (27). These investigators found no difference in hos-
pital mortality or the development of antibiotic resistance. The
addition of an aminoglycoside was associated with a greater
risk of nephrotoxicity. However, most studies in their review
used multiple-day administration of aminoglycosides for the
complete duration of antibiotic therapy as opposed to once-
daily administration which has been associated with less neph-
rotoxicity (5). Moreover, the same investigators found no ad-
vantage in febrile neutropenia when combination therapy was
used (28). A major limitation of the studies in these two meta-
analyses is that they typically had small numbers of patients
infected with potentially antibiotic-resistant bacteria, thereby
limiting any potential benefit from combination antimicrobial
therapy.
More recent studies have also attempted to evaluate the
potential benefit of combination therapy with an aminoglyco-
side for patients infected with Gram-negative bacteria. Two
large observational studies found no survival advantage of
combination therapy over monotherapy with a -lactam for
Gram-negative bacteremia (12, 23). However, Al-Hasan et al.
showed that combination therapy that included a -lactam and
fluoroquinolone was associated with a survival advantage in
less severely ill patients with Gram-negative bacteremia but
not in critically ill patients with Gram-negative bacteremia (1).
Micek et al. studied 305 patients with Pseudomonas aeruginosa
bloodstream infection and found that combination antimicro-
bial therapy was more often appropriate compared to mono-
therapy (25). In addition, use of an aminoglycoside as the
combination agent was more often associated with initially
appropriate treatment compared to using a fluoroquinolone.
Similar findings were demonstrated in patients with Pseudo-
monas aeruginosa bacteremia where the use of combination
antimicrobial therapy as empirical treatment was associated
with better 30-day survival compared to empirical mono-
therapy (8).
Although the findings in the medical literature are mixed,
there is a strong suggestion that combination antimicrobial
therapy may improve clinical outcomes for patients with seri-
ous Gram-negative bacterial infections if combination therapy
is associated with more appropriate initial antibiotic adminis-
tration. This hypothesis is further supported by a recent clinical
study showing improvements in the clinical outcomes of pa-
tients with severe sepsis and septic shock when combination
antibiotic regimens were used as empirical treatment in the
emergency department setting (26). The challenge for clini-
cians is to identify which combination regimens would be
most effective locally. This requires local Gram-negative
bacterial susceptibility data to identify whether the addition
of a fluoroquinolone or aminoglycoside will significantly im-
prove coverage over the use of -lactam or carbapenem
monotherapy (6).
Our study has several important limitations. First, the ret-
rospective nature of the study precludes any definitive assess-
ment of causality between combination antimicrobial therapy
and improved survival. Second, the study was performed at a
single center and the results may not be applicable at other
hospitals. Indeed, several studies suggest that it is important to
assess local antibiotic susceptibility patterns of Gram-negative
bacteria in order to identify optimal empirical antibiotic regi-
mens (1, 6, 12, 25). In addition, the local presence of highly
resistant strains of Gram-negative bacteria may require the
empirical use of alternative combination regimens, including
tigecycline or colistin, to maximize appropriate treatment (29).
Third, we limited our study to antibiotics routinely used at our
hospital. Therefore, our study does not provide information on
other aminoglycosides (amikacin and tobramycin) and how
they would influence the administration of appropriate ther-
apy. Finally, the availability of several new antibiotics with
Gram-negative activity (doripenem and tigecycline) were not
in general use during the study period.
Another important limitation of our study was the definition
of appropriate antimicrobial treatment that we used. This def-
inition was based on in vitro susceptibility testing alone. It is not
clear that aminoglycoside monotherapy should be considered
appropriate treatment for patients with bacteremic sepsis
despite the presence of in vitro sensitivity. This is due to the lack
of clinical data supporting such treatment for serious bacterial
infections, with the one exclusion possibly being urinary tract
infections (32). Similarly, the lack of clinical data supporting
the use of aminoglycoside monotherapy in the setting of neu-
tropenia is another limitation of this definition (28). Another
shortcoming of our definition for appropriate antimicrobial
treatment is that aminoglycosides do not kill intracellular bac-
teria such as Salmonella despite the presence of in vitro sus-
ceptibility (17). Nevertheless, this definition has been shown to
correlate with patient outcomes in studies examining a variety
of infections (21).
In conclusion, our study suggests that the use of combination
antimicrobial therapy, especially when an aminoglycoside is
used as the combination agent, is associated with more appro-
priate initial therapy of patients with severe sepsis and septic
shock due to Gram-negative bacteremia. It would appear rea-
sonable to consider empirical combination antimicrobial ther-
apy directed against Gram-negative bacteria for critically ill
patients with severe sepsis or septic shock. This recommenda-
tion would be strongest for patients with recent antibiotic ex-
posure or the local presence of antibiotic resistance among
Gram-negative bacteria commonly associated with severe sep-
sis and septic shock. The selection of empirical antibiotic reg-
imens, including combination therapy directed against Gram-
negative bacteria, should be based on local patterns of
antimicrobial susceptibility.
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